GSK 2302024A

Drug Profile

GSK 2302024A

Alternative Names: GSK2302024A; WT1-A10+AS15 ASCI

Latest Information Update: 29 Jun 2015

Price : $50

At a glance

  • Originator GlaxoSmithKline
  • Class Cancer vaccines
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Breast cancer

Most Recent Events

  • 01 Aug 2014 GlaxoSmithKline terminates phase II trial in Breast cancer (Neoadjuvant therapy, Combination therapy) in Belgium, France, Germany, Italy, Russia, the US and the UK (NCT01220128)
  • 31 Jul 2013 Phase II clinical trials in Breast cancer (neoadjuvant, in combination with standard therapy) in Belgium, Russia and USA prior to July 2013 (IM) (NCT01220128)
  • 01 Apr 2011 Phase-II clinical trials in Breast cancer (Neoadjuvant therapy, Combination therapy) in United Kingdom (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top